

SUBJECT INDEX TO VOLUME 5

Akt	576	development of	435
dysregulation of signaling in tumor cells	577	doxorubicin as	435
in control cell growth/survival	581	epidoxotom as	436
inhibitors of	580	role of androgen receptor	444
regulation of activity of	576	role of estrogen receptor	444
-Amantin	424	role of $\alpha_5\beta_1$ integrin	444
interfacial inhibition of eukaryotic RNA		targeting strategies for	444
polymerase II (POL II)	424	Anthracyclines	431
Aminoglycosides	327	activation of	431
effect on hybrid triple helix	331	apoptosis studies of	441
effect on DNA triple on	328	biological effects of	437
effect on RNA triple helix	331	clinical development of	440
recognition of triple helical nucleic acids by	327	derivatives of	443
Aminopeptidase N	281	discovery of	431,437
anticancer evaluation of	298	DNA adducts formed with	432
clinical trials of	298	effect of formaldehyde	431
function of	281	growth inhibition studies of	441
in degrading bioactive peptides	285	involvement of topoisomerase with	443
in development of malignant tumorigenesis	284	limitations in therapy of	432
in promoting angiogenesis of tumor tissues	285	mechanism of action of	432
mechanism of action of	283	to circumvent drug resistance	439
natural inhibitors of	286	Anti-angiogenic activity	68
natural substrates for	285	drug resistance with	69
peptidomimetic inhibitors of	290	limiting factors for clinical use of	68
structure characteristics of	281	side effects of	68
structure of inhibitor binding sites of	282	of microtubule-targeting drugs	68
synthetic small molecule inhibitors of	290	Anti-angiogenic therapy	115
Aminopeptidase N (APN/CD13) inhibitors	281	as cancer treatment paradigm	115
bestatin as	298	use of celecoxib	125
curcumin as	299	use of novel agents inhibiting endothelial function	125
development of	281	use of retinoids	125
non-peptide inhibitors of	295	use of thalidomide	125
Angiogenesis	116	Anticancer agents	68,583
batimastat in	118	chemical genetics based approach to discovery of	583
indocarbazole/related analogs in	123	genetically engineered biosynthesis approach of	585
induction of tumor endothelial cell apoptosis in	124	noscapine/derivatives as	68
inhibition of endothelial cell adhesion/migration in	124	structure-based drug design of	585
inhibitors growth factor receptor signaling in	120	Anti-cancer drugs	183
inhibitors of endothelial cell proliferation in	119	bis-benzimidazole as	189
inhibitors of angiogenic growth factor binding in	119	DNA helicases as targets for	183
inhibitors of other tyrosine kinase involved in	123	secondary DNA structure as target for	190
inhibitors of proteolytic enzymes of extracellular		Anticancer drug activity	3
matrix (ECM)	117	effect of tumor extracellular pH on	3
marimastat in	118	Antiparasitic drugs	413
metastat in	119	Aporphinoid alkaloids	173
miscellaneous proliferation inhibitors in	124	anticancer activities of	175
quinazoline in	123	as antitumor	173
prinomastat in	119	as cytotoxic	173
small molecule based vascular target therapy of	126	biosynthesis of	175
steroids/isoflavones in	124	pharmacological properties of	175
targeting neovasculature in	117	ATP-competitive CDK2 inhibitors	561
targeting pre-existing vasculature in	126	analysis of	561
vascular targeting agent (VTA) in	126	and adenino-mimetic scaffolds	570
Anthracycline-DNA adducts	432	and oxindole scaffold	564
Anthracycline-formaldehyde conjugates	435,444	and purine scaffold	563
daunorubicin as	435		

and pyrazole scaffold	569	aromatic ligands in.....	140
and pyrimidine scaffold.....	565	platinum antitumor complexes with aromatic N-	
binding modes of.....	561	containing ligands in.....	138
by X-ray structures.....	561	ruthenium antitumor complexes with N-donor	
role of protein-inhibitor complexes.....	561	aromatic ligands in.....	143
14-Azacamptothecin	359	Cancer	107,115,157,251,363,477
as water soluble topoisomerase I poison.....	359	acyclic sesquiterpenes in	477
Benzimidazole derivatives	400	aminopeptidases in	166
Bis-amidines	405	antisense/ribozymes/siRNA based therapies in.....	159
synthesis of prodrugs of	405	apoptotic pathways in.....	251
BQQ-neomycin.....	334	arislochic acid in.....	487
dual recognition of DNA triple helix by	334	artemisinins in	497
Breast cancer.....	99	bicyclic sesquiterpenes in.....	480
2C4-pertuzumab in.....	104	cadinene in.....	485
ABX-EGF in	100	combination therapies in	159
anti-EGFR antibodies in.....	99	cytokine gene therapy in.....	158
epidermal-growth-factor-receptor-targeted		dikdroagarofuran in	490
therapy in.....	99	dolastin-10 in.....	127
HER-2-targeted therapy in	100	environment specific tumor targeting in	161
IMC-C225 in	99	epidermal growth factor (EGF)	161
monoclonal antibody-based targeted therapy in	99	etoposide in.....	363
novel approaches to HER-2-antibody-based		extracellular matrix in	167
therapy in.....	103	fibroblast growth factor in.....	161
trastuzumab in	102	fibronectin in	167
VEGF targeted therapy in	104	folate in.....	161
Butyric acid.....	440	gene directed enzyme prodrug therapy	
Camptothecin	9,353,421	(GDEPT) in	158
analogues modified in ring E	355	helenalins in.....	487
as interfacial inhibitor	421	HMGN2/F3 peptide in.....	166
derivatives of.....	421	indocarbazole/related analogs in	123
impact of extracellular pH on development of.....	9	induction of tumor endothelial cell apoptosis in	124
Cancer cells.....	241	inhibition of endothelial cell adhesion/migration in.....	124
apoptosis in.....	241	inhibitors growth factor receptor signaling in.....	120
Cancer chemotherapy.....	65	inhibitors of endothelial cell proliferation in.....	119
agents bind to colchicines site for.....	68	inhibitors of engiogenic growth factor binding in..	119
agents bind to taxane site for	67	integrin ligands in.....	164
agents bind to vinca domain for.....	66	irofulven in	487
targeting microtubules for	65	leineridanin in.....	487
Cancer cytotoxic compounds.....	441	lymphatic vessel in	167
Cancer gene therapy.....	158	marimastat in	118
therapeutic concepts for	158	metalloproteases in	167
Cancer therapy	131	metastat in.....	119
activation of p53 in.....	131	miscellaneous proliferation inhibitors in.....	124
Cancer treatment	137	monocyclic sesquiterpenes in.....	478
metal complexes with aromatic N-containing		NG2 proteoglycan in	167
ligands in.....	137	nupharidine in.....	480
dinuclear palladium complexes with pyridine		ouinazoline in	123
derivatives on.....	142	parthenolides in	482
intercalator-platinum conjugates in	139	parviflorener in	485
lanthanum(III) antitumor complexes with N-donor		passive tumor targeting in	159
aromatic ligands in.....	144	peptidic ligands in	166
other metal complexes with N-donor aromatic		ptinomatat in.....	119
ligands in.....	145	quadrone in	493
palladium(II) antitumour complexes with N-donor		rationale for enzyme/prodrug therapy of.....	107
		replacement/overexpression strategies to.....	159
		reticulidins in.....	486
		role of molecular targeting in tumor vasculature ...	164
		small molecule based vascular target therapy of....	126
		steroids/isoflavones in	124

suberosenone in.....	494	telomere target for.....	254
suberosols in.....	486	transcription factors involved in resistance of.....	19
targeting of tumor vasculature in.....	162	triggered apoptotic pathways.....	258
targeting preexisting vasculature in.....	126	Cisplatin resistance.....	20
terpenes in.....	477	activating transcription factor 4(ATF4) in.....	22
thapsigargin in.....	484	CCAAT-binding transcription factor 2 (CTF2).....	22
tie2 in.....	166	c-Myc in.....	21
tithofolinolide in.....	483	mitochondrial transcription factor A (mtTFA) in.....	23
topoisomerase II in.....	363	other transcription factors in.....	23
torilin in.....	480	p53/p73 in.....	20
transterin in.....	161	Y-box binding protein-1 (YB-1) in.....	21
trichothecenes in.....	495	Zinc-finger factor 143 (ZNF143).....	22
tumor cell promoter targeting in.....	162	Class I phosphatidylinositol 3-kinases.....	449
tumor specific antibodies in.....	160	as therapeutic targets for oncology.....	449
tumor vaccination in.....	158	deregulation in cancer cells.....	453
vascular endothelial growth factor/receptor		Competition dialysis assay.....	340
VEG/VEGFR in.....	166	array of structures used in.....	340
vascular targeting agent (VTA) in.....	126	Competition dialysis.....	339
vernolides in.....	479	applications of.....	342
xanthanolides in.....	481	experimental procedures of.....	342
zerumbones in.....	480	for drug-nucleic acid interactions.....	339
CDK2 ATP pocket.....	561	global analysis of.....	343
structural features of.....	561	quantitative analysis of.....	350
Chemogenomics.....	61	to measure structural selectivity.....	339
Chemoprevention.....	201	Coumarin.....	30,47
combination therapy in.....	208	as anticoagulants.....	31
cross talk between the EGFR/P13K/NF B		as antioxidant.....	34
pathways in.....	205	chemical aspects of.....	47
curcumin in.....	207	cytotoxicity of.....	31
EGCG in.....	207	furanocoumarin as.....	42
EGFR signalling in.....	202	metal complexes with.....	36
NF- B signaling in.....	204	natural.....	37
P13K signalling in.....	204	preparation of chemical compounds of.....	47
resveratrol in.....	208	prevention of hepatocellular carcinomas by.....	47
Chemopreventive agents.....	201	screening system for chemicals of.....	47
interfere with deregulated signaling pathways.....	207	semi-synthetic.....	30
multiple mechanisms of action of.....	201	structure of.....	33
plant-derived.....	201	synthetic.....	30
Cisplatin.....	15,251	Coumarin compounds.....	48
and thiol-containing molecules.....	256	Cytotoxic agents.....	29
anticancer activity of.....	597	isocoumarins as.....	40
cellular DNA as target of.....	252	synthetic/natural coumarins as.....	29
cellular mechanisms of uptake/efflux of.....	256	structure of.....	33
cellular responses to.....	261	Dehydroaporphines.....	179
DNA-damaging antitumour compound.....	251	Deoxygenated anticancer agents.....	215
in cancer cells.....	251	acridines as.....	229
in DNA repair system.....	256	biological activity of.....	215
in mitogen-activated protein kinases pathways.....	260	camptothecin analogs as.....	222
in tumor suppressor p53.....	261	ellipticine analogs as.....	228
induced apoptosis by.....	16	methylenedioxy analogs as.....	223
induced mismatch repair-dependent apoptosis		podophyllotoxin analogs as.....	215
pathway.....	258	synthesis of.....	215
mechanisms of resistance of.....	18	Diamidines.....	403
multifactorial biochemical responses of.....	251	biological activation of.....	403
pharmacokinetics of.....	255	design of.....	403
reactivity with genomic DNA.....	252		
resistance of.....	15		
role of transcription factors.....	15		

prodrug approaches for	403	Enzyme/prodrug combinations	107
synthesis of	403	advantages of	107
Dication-DNA complexes	398	carboxylesterase(s)irinotecan (CE/CPT-11)	111
effect of compound shape on	398	cytochrome P450 reductase/CYP2B1/ cyclophosphamide (CYP2B1/CPA)	110
Dicationic heterocycles	392	disadvantages of	107
antiparasitic action of	392	<i>Escherichia coli</i> -glucuronidase/anthracycline glucuronide conjugates (-GLU/proDOX)	108
biological mechanism of	392	for <i>Escherichia coli</i> cytosine deaminase/5- flourocytosine (CD/5-FC)	108
Dimethylxathenone-4-acetic acid (DMXAA)	5,6-501	for <i>Escherichia coli</i> purine nucleoside purine nucleoside phosphorylase/fludarabine (PNPase/ 2-F-araA)	108
active form of	502	herpes simplex virus-thymidine kinase/ganciclovir (Hsvtk/GCV)	108
antiangiogenic action of	501	therapy by	112
antivascular effect of	501	tyrosine hydroxylase/pro VP16-IV (TH/proVP16-IV)	111
cytokine induction by	501	Ethylene	503
immunomodulatory influence of	501	Etoposide	363
in apoptosis	501	cellular repair of DNA damage by	368
in cell signaling	502	history of	363
NO induction by	501	initiation of leukemia by	369
physiological effects of	501	Flavone-8-acetic acid (FAA)	501
serotonin induction by	501	Formaldehyde	432
Distamycin	410	and butyric acid-releasing prodrugs	437
analogues of	410	in anthracycline-DNA adduct formation	432
targeting A-T-rich sequences with	410	in cells	434
target satellite repeats of	410	mediated activation of anthracyclines/compounds	433
DNA helicases	183	Formaldehyde-releasing compounds	440
as targets for RNAi in cancer treatment	195	hexamethylenetetramine as	440
effect of small molecular DNA binding drugs	185	Formaldehyde-releasing drugs	444
DNA-interacting compounds to target	185	in cancer therapies	444
inhibition by anti-tumor drug CC-1065	189	G4 DNA	190
mechanisms of	183	and RecQ helicases	191
RecQ family of	184	in anti-cancer therapy	192
DNA targets	406	in transcriptional regulation	191
in diseases	406	role in genomic stability	190
DNA-intercalating agents	186	G4 DNA binding molecules	193
anti-helicase action of	186	2,6-diamido anthraquinones as	193
DNA minor groove	389	cationic porphyrins as	194
as target	389	quindolines as	195
biological activity of	389	teraplex binding compounds as	195
compound design	389	Gene expression	320
design/analysis of	396	TFO-mutagen conjugates activation by	322
DNA interactions with	389	TFO-mutagen conjugates inhibition by	320
for antiparasitic activity	396	Glycyrrhizin	48
in cellular distribution	389	mechanisms of prevention of hepatitis by	48
in drug design	394	structure of	48
variety of	403	G-quadruplex motif	466
DNA minor groove binders	409	as tool in aptamer design	466
effect of drug/DNA vs. protein/DNA interactions	409		
identifying protein targets by	417		
satellite repeats with	409		
DNA minor groove recognition	375		
alternative heterocycles for	375		
Doxsaliform	437		
Drug development	1		
traditional vs. mechanisms-driven	1		
Drug discovery	53		
in post genomic age	53		

Helical structures	324	antimutagenic effects of	630
induction of repair <i>via</i> altered	324	antioxidant properties of	629
stimulation of recombination <i>via</i>	324	as anticancer agent.....	627
Hepatitis	48	bioavailability of.....	628
caspase-3 in.....	48	chemoprevention in animal models by.....	630
Hepatocellular carcinomas.....	47	effect of cancer cell lines.....	630
as strategy for preventing	47	food sources of	628
furanocoumarin in.....	48	human studies of.....	631
glycyrrhizin to normalize plasma ALT in	48	mechanism of anticancer activity of.....	631
IFN-therapy in	47	metabolism of	629
normalization of plasma ALT.....	47	protection against neurological	630
simple coumarins in.....	49	structure of.....	628
Heterocyclic dictations.....	389	tissue distribution of.....	629
biological properties of	389	toxicity of	632
Histone deacetylase (HDAC).....	529	Merses-DNA complexes	423
associated complexes of.....	530	effect of antibacterial agents.....	423
in cancer	530	effect of anticancer agents.....	423
regulation of transcription of.....	529	interfacial inhibition of.....	423
Histone deacetylase inhibitors	529	Microtubules	65
cellular activities of.....	530	as validated target for anti-cancer drugs	65
chemistry of.....	534	dynamics of.....	66
cinnamate type	538	mechanisms of action of drugs targeting on	66
cyclic tetrapeptide-based.....	556	structure of	66
development of.....	529	Multi-nuclear platinum drugs.....	267
hydroxamate type.....	534	cytotoxicity of.....	271
ortho-amino anillides as	546	DNA binding of.....	272
preclinical/clinical studies of.....	531	DNA coordination covalent adducts of.....	272
with non-hydroxamate/non-anilide head group	551	in chemotherapy	267
Kinetoplast	392	<i>in vitro</i> studies of.....	269
as therapeutic target.....	392	structure-activity of	270
Lanthanides	304,591	toxicity of.....	271
anticarcinogenic action of	594	Mutagenesis	322
applications of	593	TFO-mutagen conjugates induce.....	322
as anticancer agents.....	591,595	Nanosystems	306
as anticancer	594	Natural furocoumarins	42
biodistribution of	304	Natural isocoumarins	40
biological effects of.....	593	Natural pyranocoumarins	40
chemistry of.....	304	Neem leaves	149
future of.....	598	analgesic activity of.....	152
in modern cancer therapy.....	598	anticancer activity of	153
in photodynamic therapy.....	599	antidermatophytic activity of.....	152
in prevention of cancer development	594	antifertility activity of.....	150
in radioimmunotherapy	598	antifungal activity of	150
selective cytotoxicity of	597	antigenotoxic effects of.....	153
toxicity of	304	antimalarial activity of.....	150
Lanthanide bearing microparticulate systems.....	303	antiulcerogenic activity of.....	152
for multi-modality imaging	303	antiviral activity of	150
in targeted therapy of cancer	303	as antihyperglycaemic	152
-Linked polyamides	379	as antihypertensive	152
Liposomes	305	as anti-inflammatory.....	152
Lycopene.....	627	as antioxidant.....	153
absorption of.....	628	as antipyretic	152
against cardiovascular diseases.....	630	chemistry of	149
anticarcinogenic properties of.....	630	clinical trials of.....	153
		hepatoprotective effect of.....	153

immunostimulant activity of	153	chemistry of	576
in orodental protection	153	for targeted cancer therapy	575
medicinal properties of	149	inhibition of	575
neuropharmacological activity of	152	inhibitors of	578
pharmacological actions of	149	P13K/Akt signaling inhibitors	583
toxicity studies of	153	approaches for development of	583
Neomycin	333	toxicities of	583
binding mode of	333	P13K/PKB pathway	449
Neutron capture therapy	309	alternative approaches to block	455
Nitric oxide induction	503	as tool compounds to drug candidates	450
Non-small-cell cancer (NSCLC)	73	blocking of	449
chemoresistance in	73	effect of deguelin	458
cispatin/carboplatin in	75	effect of inhibitors of heat-shock protein 90	458
clinical studies of	82	effect of inositol polyphosphates	457
gemcitabine in	80	effect of phosphatidylinositol analogues	455
irinotecan in	79	effect of phospholipids	457
multidrug resistance in	74	effect of tricirbine	458
vinorelbine/taxanes in	77	in tumor cells	449
Novel anticancer targets	53	orphan inhibitors of	458
based on integrins	53	targeting ATP-binding pocket of	450
cell signal transduction pathway inhibitors as	54	3-Phosphoinoside-dependent protein kinase-1	452
drug discovery based on aminopeptidase N		deregulation in cancer cells	453
(APN) as	57	targeting kinase activity of	452
drug discovery based on cyclooxygenase-2		PKB kinase inhibitors	454
(COX-2) as	60	Polymer based systems	306
drug discovery based on endothelin receptor		Preactivated anthracyclines	434
(ETR) as	60	Proaporhines	180
drug discovery based on farnesyltransferase		Prodrugs	107
(Ftase) as	55	development of	107
drug discovery based on heat shock protein 90		for enzyme-mediated/tumor-selective therapy	107
(HSP90) as	59	Programmable DNA binding oligomers	373
drug discovery based on histone deacetylase		affinity/specificity of	373
(HDACs) as	59	and repression	382
drug discovery based on matrix metalloproteinases		binding site size of	374
(MMPs) as	54	cell/nuclear uptake of	381
drug discovery based on tyrosine kinase (TK) as	54	for control of transcription	373
in post genomic age	53	fused bicycles-benzimidazole analogues of	378
manipulators as	54	modulation of gene expression by	381
other targets of	61	pairing rules in	373
tumor angiogenesis inhibitors as	53	polyamide binding motifs of	375
N-oxides	179	synthetic methods to	379
Nucleosomes	380	Prostate cancer	603
Osthole	49	angiogenesis as target for drug treatment of	607
chemical aspects of	49	bisphosphonates in	608
methoxy-group at position-7	49	chemoprevention of	609
Oxaporhines	178	chemotherapy of	608
P13K	576	drug therapy for	603
dysregulation of signaling in tumor cells	576	endothelin in	608
inhibitors of	579	epidermal growth factor receptor tyrosine kinase	
in control cell growth/survival	581	inhibitors in	609
regulation of activity of	576	estrogen therapy of	607
P13K/Akt signaling	575	gene therapy of	609
anticancer agents for targeting	578	hormonal manipulation of	603
biology of	576	immunotherapy of	609
		molecular genetics of	603
		role of anti-androgens	606
		role of corticosteroids	607

role of ketoconazole.....	607	Selenoenzymes.....	639
role of lutenising hormone releasing hormone analogues.....	605	role of.....	639
role of non-steroidal anti-androgens.....	606	Serotonin induction.....	504
role of steroidal anti-androgens.....	606	Sesquiterpenes.....	477
strontium-89 in.....	608	as natural products.....	477
Protein-nucleic acid interactions.....	421	role in cancer growth.....	477
interfacial inhibitors of.....	421	Sesquiterpene lactones.....	239,246
orthosteric/allosteric/interfacial inhibitors of.....	421	anti-cancer potential of.....	239
Pyrlum-type ions.....	501	anti-inflammatory effect of.....	243
5,6-dimethylxanthenone-4-acetic acid (DMXAA).....	501	anti-metastasis activity of.....	243
electrochemistry of.....	502	arctigenin as.....	247
electron transfer mechanism by.....	501	arctiin as.....	247
for anticancer drugs.....	501	arteminolides as.....	248
from flavone-8-acetic acid from.....	501	bioactivity of.....	239
photochemistry of.....	502	costunolids as.....	246
synthesis of.....	502	helenalin as.....	246
Quadruplex-forming.....	463	<i>in vitro</i> studies of.....	241
as tools in anticancer therapy.....	463	<i>in vivo</i> animal models of.....	243
energetics aspects of.....	467	induction of oxidative stress.....	244
energetics of quadruplex-ligand interaction.....	471	inhibition of enzymes in cancer development by... ..	546
in anticancer therapy.....	465	inhibition of MAPK signaling pathway in.....	245
in aptamers design.....	463	inhibition on nuclear transcription factor NF- B pathway by.....	245
kinetics of folding/unfolding of.....	471	molecular mechanisms of.....	239,244
oligonucleotides of.....	463	parthenolide as.....	246
structure of.....	463	sensitization activity of.....	242
thermodynamics of.....	467	structure of.....	239
thermodynamics of modified type.....	470	Solid tumor physiology.....	1
Quinolines.....	503	features of.....	1
Radionuclides.....	307	Steroid sulfatase.....	507
RNA interference.....	195	biochemical/structural features of.....	507
chemotherapeutic approach to.....	195	in hormone-dependent cancer.....	509
Satellite repeats.....	411	inhibitors from screening.....	519
molecular consequences of polyamide binding to.....	411	substrate-based inhibitors of.....	510
Selenium.....	637	product-like inhibitors of.....	510
anti-tumorigenic metabolites of.....	639	Steroid sulfatase inhibitors.....	507
as anti-angiogenic agent.....	641	assays to test.....	510
biochemistry of.....	638	estrogenicity of.....	524
effects on carcinogen metabolism.....	639	in therapy of breast cancer.....	507
effects on immunity.....	639	<i>in vivo</i> efficacy of.....	523
in apoptosis.....	640	inhibition of carbonic anhydrases by.....	523
in DNA repair.....	641	inhibition of STS by.....	522
mechanisms of cancer prevention by.....	638	irreversible inhibition of.....	522
metabolism of.....	648	mode of inhibitions of.....	521
physicochemical properties of.....	638	non-steroidal aryl sulfamates as.....	514
toxicity of.....	648	pharmacokinetics of.....	524
Selenium derivatives.....	637	pharmacology of.....	522
antitumor activity of.....	645	reversible inhibition of.....	521
as cancer preventive agents.....	637	SAR of.....	520
chemopreventive activity of.....	641	sterpodal aryl sulfamates as.....	513
effects on carcinogen metabolism.....	639	substrate-based inhibitors of.....	510
effects on immunity.....	639	sulfate surrogates for.....	510
history of.....	637	Sulfo-quinovosyl-acyl-glycerol (SQAG).....	613
physicochemical properties of.....	638	as anti-cancer agent.....	613
		as eukaryotic DNA polymerase inhibitor.....	613
		derivatives of.....	614
		effect of reaction conditions/inhibition of DNA polymerase / by.....	618

inhibitory effects on DNA polymerase activity of ..614	
modes of inhibition of DNA polymrase / by.....617	
three-dimensional modeling of interaction of619	
Topoisomerase I-DNA covalent binary complex353	
D/E rings in binding to.....353	
Topoisomerase II364	
actions of etoposide against366	
cellular target of366	
DNA cleavage complexes of.....365	
effect on catalytic cycle of364	
isoforms of364	
mechanism of action of367	
structure-activity relationships of.....367	
Triplex-forming oligonucleotides319	
tools for modulation of gene expression319	
Tumor acidosis 2	
Tumor hypoxia 3	
Tumor pH gradient 2	
Tumor physiology 1	
impact of 1	
impact on camptothecin-based drug development..... 1	
Tumor tissue..... 157	
for delivery of therapeutic genes 157	
gene delivery techniques in 157	
targets in 157	
Werner and bloom syndrome 189	
inhibition of 189	